Exciva
https://www.exciva.com/Therapeutics
Exciva is a clinical-stage biopharmaceutical company focused on developing novel therapies for behavioral symptoms associated with Alzheimer's disease (AD). The company is advancing Deraphan, a combination therapy comprising two clinically validated compounds including a new chemical entity, aiming to provide a differentiated safety and efficacy profile for agitation in AD patients.
Leadership & Board
- Current Number of Employees
- 8
- Current LinkedIn Followers
- 778
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $51M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $51M
- Latest Funding Round
- Series B
- Post-Money Valuation
- ―
Employee Trend
Exciva had 8 employees as of October 12, 2026. The number of employees increased by 1 (14.29%) week-over-week.
8Latest Employee Count
1(14.29%)Week-Over-Week Change
Social Trend
Exciva had 778 followers as of October 12, 2026. The number of followers increased by 4 (0.52%) week-over-week.
778Latest Followers Count
4(0.52%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 20, 2026 | Series B | $51.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| CARMA Fund | Series B |
| Andera Partners | Series B |
| Fountain Healthcare Partners | Series B |
| Gimv | Series B |
| Modi Ventures | Series B |
| EQT Life Sciences | Series B |
| LifeArc | Series B |
| LBBW | Series B |
Similar Companies
A snapshot of private companies similar to Exciva, helping you discover and navigate related company profiles.
Related News and Analysis
